FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Nephron

Drug and asset intelligence for Nephron with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Micro Labs →

Recent signals(2)

RegulatoryJuly 20, 2026

Nephron's Levalbuterol Hydrochloride ANDA215217 Receives Approval Status

Nephron's ANDA for Levalbuterol Hydrochloride has received an approval status (AP) from the FDA.

StrategyJune 19, 2026

FDA Approves ANDA216272 for Norepinephrine Bitartrate by Nephron

The FDA has approved ANDA216272, a generic formulation of Norepinephrine Bitartrate, submitted by Nephron.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Nephron

July 20, 2026 · N/A

Topline Data

Micro Labs — Nephron

June 19, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Bronchodilator →

Cardiovascular →

Cardiovascular · Vasopressor →

Respiratory →

Respiratory · Bronchodilator →

Vasopressor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.